NewAmsterdam Pharma Company N.V. (NAMS)
NASDAQ: NAMS · Real-Time Price · USD
18.03
+0.21 (1.18%)
Nov 4, 2024, 4:00 PM EST - Market closed

Company Description

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease.

It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.

The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Company logo
Country Netherlands
Founded 2019
Industry Biotechnology
Sector Healthcare
Employees 29
CEO Michael Davidson

Contact Details

Address:
Gooimeer 2-35
Naarden, 1411 DC
Netherlands
Phone 31 35 206 2971
Website newamsterdampharma.com

Stock Details

Ticker Symbol NAMS
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001936258
ISIN Number NL00150012L7
SIC Code 2834

Key Executives

Name Position
Dr. Michael Harvey Davidson FACC, Facp., M.D. Chief Executive Officer, President, Executive Board Member and Director
Dr. Johannes Jacob Pieter Kastelein FESC, M.D., Ph.D. Founder, Chief Scientific Officer, Member of Executive Board and Director
Mayur Amrat Somaiya Chief Financial Officer
Juliette Audet M.B.A., M.Sc. Chief Business Officer
Douglas F. Kling Chief Operating Officer
Louise Kooij Chief Accounting Officer
Matthew Philippe Executive Vice President &Head of Investor Relations
Jim Jacobson Chief Legal Officer and Secretary
Bob Rambo Executive Vice President of Marketing
Dr. Marc Ditmarsch M.D. Chief Development Officer

Latest SEC Filings

Date Type Title
Oct 28, 2024 20-F/A Filing
Oct 18, 2024 8-K Current Report
Oct 1, 2024 144 Filing
Aug 23, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Aug 12, 2024 EFFECT Notice of Effectiveness
Aug 9, 2024 POS AM Post-Effective amendments for registration statement
Aug 9, 2024 8-K Current Report
Aug 9, 2024 424B5 Filing
Aug 7, 2024 10-Q Quarterly Report
Aug 7, 2024 8-K Current Report